Neuroblastoma - historical

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 01:41, 25 June 2023 by Warner-admin (talk | contribs) (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study")
Jump to navigation Jump to search

Back to Top

Section editor transclusions The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main neuroblastoma page for current regimens.

2 regimens on this page
2 variants on this page


High Risk

COG ANBL0532 Regimen A

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Park et al. 2019 (COG ANBL0532) Phase 3 (C) COG ANBL0532 Regimen B Inferior EFS

Induction

Chemotherapy, Cycle 1 (CPM + TOPO)

  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 13.3 mg/kg iV over 30 to 60 minutes once per day on days 1 to 5
    • > 12 kg: 400 mg/m2 IV over 30 to 60 minutes once per day on days 1 to 5
  • Topotecan (Hycamtin) 1.2 mg/m2 IV over 30 minutes once per day on days 1 to 5

21-day cycle

Chemotherapy, Cycle 2 (CPM + TOPO)

  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 13.3 mg/kg iV over 30 to 60 minutes once per day on days 1 to 5
    • > 12 kg: 400 mg/m2 IV over 30 to 60 minutes once per day on days 1 to 5
  • Topotecan (Hycamtin) 1.2 mg/m2 IV over 30 minutes once per day on days 1 to 5

21-day cycle

Supportive Therapy, Cycle 2

  • Filgrastim (Neupogen) 5 mcg/kg SC or IV once per day, beginning 24 hours after completion of chemotherapy and continuing until ANC > 1000/μL
  • Filgrastim (Neupogen) 10 mcg/kg SC or IV once per day beginning once ANC > 1000/μL and continuing until PBSC harvest is complete
  • PBSC harvest on day 14

21-day cycle

Chemotherapy, Cycle 3 (CDDP + ETOP)

  • Cisplatin (Platinol) by the following weight-based criteria:
    • ≤ 12 kg: 1.66 mg/kg IV over 1 hour once per day on days 1 to 4
    • > 12 kg: 50 mg/m2 IV over 1 hour once per day on days 1 to 4
  • Etoposide (Vepesid) by the following weight-based criteria:
    • ≤ 12 kg: 6.67 mg/kg IV over 1 hour once per day on days 1 to 3
    • > 12 kg: 200 mg/m2 IV over 1 hour once per day on days 1 to 3

Chemotherapy, Cycle 4 (CPM + DOXO + VCR)

  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 70 mg/kg iV over 6 hours once per day on days 1 to 2
    • > 12 kg: 2100 mg/m2 IV over 6 hours once per day on days 1 to 2
  • Vincristine (Oncovin) by the following criteria:
    • < 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 1 to 3
    • ≥ 12 months and > 12 kg: 0.097 mg/m2 or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 1 to 3
    • ≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 1 to 3
  • Doxorubicin (Adriamycin) by the following weight-based criteria:
    • ≤ 12 kg: 0.83 mg/kg iV over 24 hours once per day on days 1 to 3
    • > 12 kg: 25 mg/m2 IV over 24 hours once per day on days 1 to 3

21-day cycle

Supportive Therapy, Cycle 4 (CPM + DOXO + VCR)

  • Mesna (Mesnex) by the following weight-based criteria:
    • ≤ 12 kg: 14 mg/kg IV over 15 minutes immediately prior to each cyclophosphamide dose and again at 4 and 8 hours after each cyclophosphamide infusion
    • > 12 kg: 420 mg/m2 IV over 15 minutes immediately prior to each cyclophosphamide dose and again at 4 and 8 hours after each cyclophosphamide infusion

21-day cycle

Chemotherapy, Cycle 5 (CDDP + ETOP)

  • Cisplatin (Platinol) by the following weight-based criteria:
    • ≤ 12 kg: 1.66 mg/kg IV over 1 hour once per day on days 1 to 4
    • > 12 kg: 50 mg/m2 IV over 1 hour once per day on days 1 to 4
  • Etoposide (Vepesid) by the following weight-based criteria:
    • ≤ 12 kg: 6.67 mg/kg IV over 1 hour once per day on days 1 to 3
    • > 12 kg: 200 mg/m2 IV over 1 hour once per day on days 1 to 3

21-day cycle

Chemotherapy, Cycle 6 (CPM + DOXO + VCR)

  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 70 mg/kg iV over 6 hours once per day on days 1 to 2
    • > 12 kg: 2100 mg/m2 IV over 6 hours once per day on days 1 to 2
  • Vincristine (Oncovin) by the following criteria:
    • < 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 1 to 3
    • ≥ 12 months and > 12 kg: 0.097 mg/m2 or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 1 to 3
    • ≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 1 to 3
  • Doxorubicin (Adriamycin) by the following weight-based criteria:
    • ≤ 12 kg: 0.83 mg/kg iV over 24 hours once per day on days 1 to 3
    • > 12 kg: 25 mg/m2 IV over 24 hours once per day on days 1 to 3

21-day cycle

Supportive Therapy, Cycle 6 (CPM + DOXO + VCR)

  • Mesna (Mesnex) by the following weight-based criteria:
    • ≤ 12 kg: 14 mg/kg IV over 15 minutes immediately prior to each cyclophosphamide dose and again at 4 and 8 hours after each cyclophosphamide infusion
    • > 12 kg: 420 mg/m2 IV over 15 minutes immediately prior to each cyclophosphamide dose and again at 4 and 8 hours after each cyclophosphamide infusion

21-day cycle


Consolidation, single autologous HSCT

Chemotherapy, High Dose with PBSC Support

  • Melphalan (Alkeran) by the following criteria:
    • ≤ 12 kg and GFR ≥ 100 mL/min: 2.3 mg/kg IV over 15 to 30 minutes once per day on days -7, -6, -5
    • > 12 kg and GFR ≥ 100 mL/min: 70 mg/m2 IV over 15 to 30 minutes once per day on days -7, -6, -5
    • ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 2 mg/kg IV over 15 to 30 minutes once per day on days -7, -6, -5
    • > 12 kg and GFR between 100 mL/min and 60 mL/min: 60 mg/m2 IV over 15 to 30 minutes once per day on days -7, -6, -5
  • Etoposide (Vepesid) by the following criteria:
    • ≤ 12 kg and GFR ≥ 100 mL/min: 11.3 mg/kg IV over 24 hours once per day on days -7, -6, -5, -4
    • > 12 kg and GFR ≥ 100 mL/min: 338 mg/m2 IV over 24 hours once per day on days -7, -6, -5, -4
    • ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 6.7 mg/kg IV over 24 hours once per day on days -7, -6, -5, -4
    • > 12 kg and GFR between 100 mL/min and 60 mL/min: 200 mg/m2 IV over 24 hours once per day on days -7, -6, -5, -4
  • Carboplatin (Paraplatin) by the following criteria:
    • ≤ 12 kg and GFR ≥ 100 mL/min: 14.2 mg/kg IV over 24 hours once per day on days -7, -6, -5, -4
    • > 12 kg and GFR ≥ 100 mL/min: 425 mg/m2 IV over 24 hours once per day on days -7, -6, -5, -4
    • ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 4.1 AUC using Calvert Formula (Max Dose = 300 mg/m2) IV over 24 hours once per day on days -7, -6, -5, -4
    • > 12 kg and GFR between 100 mL/min and 60 mL/min: Use the lowest of either 4.1 AUC using Calvert Formula or 10 mg/kg IV over 24 hours once per day on days -7, -6, -5, -4
  • PBSC on day 0

36-day cycle

Supportive therapy,

  • Filgrastim (Neupogen) 5 mcg/kg SC or IV once per day starting on day 0 and continuing until post-nadir ANC > 2000/μL for 3 consecutive days

36-day cycle


Maintenance

Chemotherapy

  • Isotretinoin (Accutane) by the following weight-based criteria:
    • ≤ 12 kg: 5.33 mg/kg (Round dose to nearest 10 mg) PO twice per day on days 1 to 14
    • > 12 kg: 160 mg/m2 (Round dose to nearest 10 mg) PO twice per day on days 1 to 14

28-day cycle for 6 cycles

References

  1. COG ANBL0532: Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 Aug 27;322(8):746-755. link to original article link to PMC article PubMed Clinical Trial Registry

COG ANBL 0032 Regimen A

Post-consolidation, Study Phase

Study Dates of enrollment Evidence
Yu et al. 2010 (COG ANBL0032) 2001-2009 Non-randomized part of phase 3 RCT

Chemotherapy

  • Isotretinoin (Accutane) by the following weight-based criteria:
    • > 12 kg: 80 mg/m2 (Round to nearest 10 mg) PO twice per day on days 11 to 24
    • ≤ 12 kg: 2.67 mg/kg (Round to nearest 10 mg) PO twice per day on days 11 to 24

25-day cycle for 6 cycles

References

  1. COG ANBL0032: Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34. link to original article link to PMC article PubMed Clinical Trial Registry
    1. Update: Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 Apr 15;27(8):2179-2189. Epub 2021 Jan 27. link to original article link to PMC article PubMed

COG A3973 with Myeloablative Therapy

Study Dates of enrollment Evidence
Kreissman et al. 2013 (COG A3973) 2001-2006 Non-randomized part of phase 3 RCT

Induction

Chemotherapy, Cycles 1, 2, 4, and 6

  • Vincristine (Oncovin) by the following criteria:
    • < 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 0 to 2
    • ≥ 12 months and > 12 kg: 0.67 mg/m2 or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg/m2 in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 0 to 2
    • ≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 0 to 2
  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 70 mg/kg IV over 6 hours once per day on days 0, 1
    • > 12 kg: 2100 mg/m2 IV over 6 hours once per day on days 0, 1
  • Doxorubicin (Adriamycin) by the following weight-based criteria:
    • ≤ 12 kg: 0.83 mg/kg IV over 24 hours once per day on days 0 to 2
    • > 12 kg: 25 mg/m2 IV over 24 hours once per day on days 0 to 2

21-day cycles PBSC Harvest occurs on Week 6 of treatment (Cycle 2)

Supportive therapy, Cycle 1, 2, 4, and 6

  • Mesna (Mesnex) by the following weight-based criteria:
    • ≤ 12 kg: 10 mg/kg IV over 15 minutes immediately prior to each cyclophosphamide dose and again at 4 and 8 hours after each cyclophosphamide infusion on days 0, 1
    • > 12 kg: 420 mg/m2 IV over 15 minutes immediately prior to each cyclophosphamide dose and again at 3, 6, and 9 hours after each cyclophosphamide infusion on days 0, 1
  • Filgrastim (Neupogen) 5 mcg/kg SC or IV once per day starting on day 3 and continuing until post-nadir ANC > 1500/μL

21-day cycles

Chemotherapy, Cycles 3 and 5

  • Cisplatin (Platinol) by the following weight-based criteria:
    • ≤ 12 kg: 1.66 mg/kg IV over 1 hour once per day on days 0 to 3
    • > 12 kg: 50 mg/m2 IV over 1 hour once per day on days 0 to 3
  • Etoposide (Vepesid) by the following weight-based criteria:
    • ≤ 12 kg: 6.67 mg/kg IV over 2 hours once per day on days 0 to 2
    • > 12 kg: 200 mg/m2 IV over 2 hours once per day on days 0 to 2

21-day cycles

Supportive therapy, Cycles 3 and 5

  • Filgrastim (Neupogen) 5 mcg/kg SC or IV once per day starting on day 4 and continuing until post-nadir ANC > 1500/μL

21-day cycles


Consolidation

Chemotherapy

  • Carboplatin (Paraplatin) by the following criteria:
    • ≤ 12 kg and GFR ≥ 100 mL/min: 14.2 mg/kg IV over 24 hours once per day on days -7, -6, -5, -4
    • > 12 kg and GFR ≥ 100 mL/min: 425 mg/m2 IV over 24 hours once per day on days -7, -6, -5, -4
    • ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: Use the lowest of either 4.1 AUC using Calvert Formula or 10 mg/kg IV over 24 hours once per day on days -7, -6, -5, -4
    • > 12 kg and GFR between 100 mL/min and 60 mL/min: 4.1 AUC using Calvert Formula (Max Dose = 300 mg/m2) IV over 24 hours once per day on days -7, -6, -5, -4
  • Etoposide (Vepesid) by the following criteria:
    • ≤ 12 kg and GFR ≥ 100 mL/min: 11.3 mg/kg IV over 24 hours once per day on days -7, -6, -5, -4
    • > 12 kg and GFR ≥ 100 mL/min: 338 mg/m2 IV over 24 hours once per day on days -7, -6, -5, -4
    • ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 6.7 mg/kg IV over 24 hours once per day on days -7, -6, -5, -4
    • > 12 kg and GFR between 100 mL/min and 60 mL/min: 200 mg/m2 IV over 24 hours once per day on days -7, -6, -5, -4
  • Melphalan (Alkeran) by the following criteria:
    • ≤ 12 kg and GFR ≥ 100 mL/min: 2.3 mg/kg IV over 15 to 30 minutes once per day on days -7, -6, -5
    • > 12 kg and GFR ≥ 100 mL/min: 70 mg/m2 IV over 15 to 30 minutes once per day on days -7, -6, -5
    • ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 2 mg/kg IV over 15 to 30 minutes once per day on days -7, -6, -5
    • > 12 kg and GFR between 100 mL/min and 60 mL/min: 60 mg/m2 IV over 15 to 30 minutes once per day on days -7, -6, -5
  • PBSC on day 0

Maintenance, "Post Consolidation" Isotretinoin

Chemotherapy

  • Isotretinoin (Accutane) by the following weight-based criteria:
    • ≤ 12 kg: 5.33 mg/kg (Round dose to nearest 10 mg) PO twice per day on days 1 to 14
    • > 12 kg: 160 mg/m2 (Round dose to nearest 10 mg) PO twice per day on days 1 to 14

28-day cycle for 6 cycles

References

  1. COG A3973: Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep;14(10):999-1008. Epub 2013 Jul 25. link to original article link to PMC article PubMed Clinical Trial Registry
    1. Subgroup analysis: von Allmen D, Davidoff AM, London WB, Van Ryn C, Haas-Kogan DA, Kreissman SG, Khanna G, Rosen N, Park JR, La Quaglia MP. Impact of Extent of Resection on Local Control and Survival in Patients from the COG A3973 Study with High-Risk Neuroblastoma. J Clin Oncol. 2017 Jan 35;2:208-216 link to original article link to PMC article link to PubMed

COG A3973 without Myeloablative Therapy

Study Dates of enrollment Evidence
Kreissman et al. 2013 (COG A3973) 2001-2006 Non-randomized part of phase 3 RCT

Induction

Chemotherapy, Cycles 1, 2, 4, and 6

  • Vincristine (Oncovin) by the following criteria:
    • < 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 0 to 2
    • ≥ 12 months and > 12 kg: 0.67 mg/m2 or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg/m2 in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 0 to 2
    • ≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once per day prior to doxorubicin on days 0 to 2
  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 70 mg/kg IV over 6 hours once per day on days 0, 1
    • > 12 kg: 2100 mg/m2 IV over 6 hours once per day on days 0, 1
  • Doxorubicin (Adriamycin) by the following weight-based criteria:
    • ≤ 12 kg: 0.83 mg/kg IV over 24 hours once per day on days 0 to 2
    • > 12 kg: 25 mg/m2 IV over 24 hours once per day on days 0 to 2

21-day cycles PBSC Harvest occurs on Week 6 of treatment (Cycle 2)

Supportive therapy, Cycle 1, 2, 4, and 6

  • Mesna (Mesnex) by the following weight-based criteria:
    • ≤ 12 kg: 10 mg/kg IV over 15 minutes immediately prior to each cyclophosphamide dose and again at 4 and 8 hours after each cyclophosphamide infusion on days 0, 1
    • > 12 kg: 420 mg/m2 IV over 15 minutes immediately prior to each cyclophosphamide dose and again at 3, 6, and 9 hours after each cyclophosphamide infusion on days 0, 1
  • Filgrastim (Neupogen) 5 mcg/kg SC or IV once per day starting on day 3 and continuing until post-nadir ANC > 1500/μL

21-day cycles

Chemotherapy, Cycles 3 and 5

  • Cisplatin (Platinol) by the following weight-based criteria:
    • ≤ 12 kg: 1.66 mg/kg IV over 1 hour once per day on days 0 to 3
    • > 12 kg: 50 mg/m2 IV over 1 hour once per day on days 0 to 3
  • Etoposide (Vepesid) by the following weight-based criteria:
    • ≤ 12 kg: 6.67 mg/kg IV over 2 hours once per day on days 0 to 2
    • > 12 kg: 200 mg/m2 IV over 2 hours once per day on days 0 to 2

21-day cycles

Supportive therapy, Cycles 3 and 5

  • Filgrastim (Neupogen) 5 mcg/kg SC or IV once per day starting on day 4 and continuing until post-nadir ANC > 1500/μL

21-day cycles


Maintenance, Cyclophosphamide and Topotecan

Chemotherapy, 3 cycles

  • Cyclophosphamide (Cytoxan) by the following weight-based criteria:
    • ≤ 12 kg: 8.33 mg/kg IV over 30 minutes once per day on days 0 to 4
    • > 12 kg: 250 mg/m2 IV over 30 minutes once per day on days 0 to 4
  • Topotecan (Hycamtin) by the following weight-based criteria:
    • ≤ 12 kg: 0.025 mg/kg IV over 30 minutes once per day on days 0 to 4
    • > 12 kg: 0.75 mg/m2 IV over 30 minutes once per day on days 0 to 4

21-day cycle

Supportive therapy, 3 cycles

  • Mesna (Mesnex) by the following weight-based criteria:
    • ≤ 12 kg: 1.7 mg/kg IV over 15 minutes immediately prior to each cyclophosphamide dose and again at 4 and 8 hours after each cyclophosphamide infusion on days 0, 1
    • > 12 kg: 50 mg/m2 IV over 15 minutes immediately prior to each cyclophosphamide dose and again 3 hours after each cyclophosphamide infusion on days 0, 1
  • Filgrastim (Neupogen) 5 mcg/kg SC or IV once per day starting on day 5 and continuing until post-nadir ANC > 1500/μL

21-day cycles


Maintenance, "Post Maintenance" Isotretinoin

Chemotherapy, 6 cycles

  • Isotretinoin (Accutane) by the following weight-based criteria:
    • ≤ 12 kg: 5.33 mg/kg (Round dose to nearest 10 mg) PO twice per day on days 1 to 14
    • > 12 kg: 160 mg/m2 (Round dose to nearest 10 mg) PO twice per day on days 1 to 14

28-day cycle

References

  1. COG A3973: Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep;14(10):999-1008. Epub 2013 Jul 25. link to original article link to PMC article PubMed Clinical Trial Registry
    1. Subgroup analysis: von Allmen D, Davidoff AM, London WB, Van Ryn C, Haas-Kogan DA, Kreissman SG, Khanna G, Rosen N, Park JR, La Quaglia MP. Impact of Extent of Resection on Local Control and Survival in Patients from the COG A3973 Study with High-Risk Neuroblastoma. J Clin Oncol. 2017 Jan 35;2:208-216 link to original article link to PMC article link to PubMed

Relapsed or refractory

Cyclophosphamide monotherapy

Regimen

Study Evidence
Thurman et al. 1964 Non-randomized

Chemotherapy

References

  1. Thurman WG, Fernbach DJ, Sullivan MP. Cyclophosphamide therapy in childhood neuroblastoma. N Engl J Med. 1964 Jun 18;270:1336-40. link to original article PubMed

Cyclophosphamide & Vincristine

Regimen

Study Evidence
Evans et al. 1969 Non-randomized

Chemotherapy

References

  1. Evans AE, Heyn RM, Newton WA Jr, Leikin SL. Vincristine sulfate and cyclophosphamide for children with metastatic neuroblastoma. JAMA. 1969 Feb 17;207(7):1325-7. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Neuroblastoma_-_historical&oldid=74266"